N-3 fatty acid supplementation to routine statin treatment inhibits platelet function, decreases patients' daytime blood pressure, and improves inflammatory status

European Journal of Clinical Pharmacology

Volumn 68, Issue 8, 2012, Pages 1139-1146

  Doenyas Barak, Keren ^a   Berman, Sylvia ^a   Abu Hamad, Ramzia ^a   Golik, Ahuva ^a   Rahimi Levene, Naomi ^a   Efrati, Shai ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

Blood pressure; Inflammation; N 3 fatty acid; Platelets function; Statins

Indexed keywords

ALPHA TOCOPHEROL; ATORVASTATIN; CHOLESTEROL; DOCOSAHEXAENOIC ACID; HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ICOSAPENTAENOIC ACID; INTERLEUKIN 6; ISOPROSTANE DERIVATIVE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OMEGA 3 FATTY ACID; OMEGA 950; PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR 1; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; SOYBEAN OIL; STAT8 ISOPROSTANE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE CONTROL; DRUG EFFICACY; DRUG MECHANISM; ENDOTHELIAL DYSFUNCTION; FEMALE; HEART RATE; HUMAN; HYPERCHOLESTEROLEMIA; INFLAMMATION; LIPID BLOOD LEVEL; MALE; OXIDATIVE STRESS; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PULSE WAVE; SUPPLEMENTATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE FUNCTION; TREATMENT DURATION;

BLOOD PLATELETS; BLOOD PRESSURE; DIETARY SUPPLEMENTS; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; ENDOTHELIUM, VASCULAR; FATTY ACIDS, OMEGA-3; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; INFLAMMATION; INTERLEUKIN-6; LIPID METABOLISM; MALE; MIDDLE AGED; OXIDATIVE STRESS; PLASMINOGEN ACTIVATOR INHIBITOR 1; STAT TRANSCRIPTION FACTORS;

EID: 84866524736     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-012-1235-4     Document Type: Article

References (29)

1. Marchioli R, Barzi F, Bomba E, Chieffo C, Di Gregorio D, Di Mascio R, GISSI-Prevenzione Investigators et al (2002) Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-Prevenzione. Circulation 105(16):1897-1903.
2. Daviglus ML, Stamler J, Orencia AJ, Dyer AR, Liu K, Greenland P et al (1997) Fish consumption and the 30-year risk of fatal myocardial infarction. NEJM 336:1946-1053.
3. De Ceterina R, Madonna R, Zucchi R, Tersesa M (2003) Antiarrhythmic effect of omega-3 fatty acids: from epidemiology to bedside. Am Heart J 146(3):420-430.
4. Krauss RM, Eckel RH, Howard B, Appel LJ, Daniels SR, Deckelbaum RJ et al AHA dietary guidelines: revision 2000: A statement for healthcare professionals from the nutrition committee of the American Heart Association. Circulation 102:2284-2299.
5. London B, Albert C, Anderson ME, Giles WR, Van Wagoner DR, Balk E et al (2007) Omega-3 fatty acids and cardiac arrhythmias: prior studies and recommendations for future research: a report from the national heart, lung, and blood institute and office of dietary supplements omega-3 fatty acids and their role in cardiac arrhythmogenesis. Circulation 116:e320-e335.
6. Woodman RJ, Mori TA, Burke V, Puddey IB, Barden A, Watts GF et al (2003) Effects of purified eicosapentaenoic acid and docosahexaenoic acid on platelet, fibrilolytic and vascular function in Type 2 diabetic patients. Atherosclerosis 166:85-93.
7. Fahs C, Yan H, Ranadive S, Rossow L, Agiovlasitis S, Ket Wet al (2010) The effect of acute fish-oil supplementation on endothelial function and arterial stiffness following a high-fat meal. Appl Physiol Nutr Metab 35(3):294-302.
8. McVeigh GE, Brennan GM, Johnston GD, McDermott BJ, McGrath LT, Henry WR et al (1993) Dietary fish oil augments nitric oxide production or release in patients with type 2 (noninsulin- dependent) diabetes mellitus. Diabetologia 36(1):33- 38.
9. Ferguson JF, Phillips CM, McMonagle J, Pérez-Martínez P, Shaw DI, Lovegrove JA et al (2010) NOS3 gene polymorphisms are associated with risk markers of cardiovascular disease, and interact with omega-3 polyunsaturated fatty acids. Atherosclerosis. Mar 27.
10. Pischon T, Hankinson SE, Hotamisligil GS, Rifai N, Willett WC, Rimm EB (2003) Habitual dietary intake of n-3 and n-6 fatty acids in relation to inflammatory markers among US men and women. Circulation 15;108(2):155-160.
11. Sala-Vila A, Cofán M, Pérez-Heras A, Núñez I, Gilabert R, Junyent M et al (2010) Fatty acids in serum phospholipids and carotid intima-media thickness in Spanish subjects with primary dyslipidemia. Am J Clin Nutr. May 12.
12. Cholesterol Treatment Trialists' (CTT) Collaborators (2005) Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90, 056 participants in 14 randomised trials of statins. Lancet 366:1267-1278.
13. Davignon J (2004) Beneficial cardiovascular pleiotropic effects of statins. Circulation 109(suppl):III-39-III-43.
14. Nissen S (2004) High-dose statins in acute coronary syndromes: not just lipid levels. JAMA 292:1365-1367.
15. Saito Y, Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Ishikawa Yet al (2008) JELIS Investigators, Japan. Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: sub-analysis of primary prevention cases from the Japan EPA Lipid Intervention Study (JELIS). Atherosclerosis 200(1):135-140.
16. Durrington PN, Bhatnagar D, Mackness MI, Morgan J, Julier K, Khan MA et al (2001) An omega-3 polyunsaturated fatty acid concentrate administered for one year decreased triglycerides in simvastatin treated patients with coronary heart disease and persisting hypertriglyceridaemia. Heart 85:544-548.
17. U.S. Food and Drug Administration Centre for Drug Evaluation and Research (1992) Approved Drug Products With Therapeutic Equivalence Evaluation (Orange Book), 12th edn. U.S. Department of Health and Human Services, Washington, DC.
18. Tanaka K, Ishikawa Y, Yokoyama M, Origasa H, Matsuzaki M, Saito Y, JELIS Investigators, Japan et al (2008) Japan. Reduction in the recurrence of stroke by eicosapentaenoic acid for hypercholesterolemic patients: subanalysis of the JELIS trial. Stroke 39(7):2052-2058.
19. Carroll D, Roth M (2002) Evidence for the cardioprotective effects of omega-3 fatty acids. Ann Pharmacother 36:1950-1956.
20. Lichtenstein A (2005) Remarks on clinical data concerning dietary supplements that affect antithrombotic therapy. Thromb Res 117:71-73.
21. Kromhout D, Giltay E, Geleijnse J, Alpha Omega Trial Group (2010) N-3 fatty acids and cardiovascular events after myocardial infarction. N Engl J Med 363:2015-2026.
22. Liao JK (2005) Effects of statins on 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition beyond low-density lipoprotein cholesterol. Am J Cardiol 96(5A):24F-33F.
23. Mangalmurti SS, DavidsonMH The Incremental Value of Lipids and Inflammatory Biomarkers in Determining Residual Cardiovascular Risk. Curr Atheroscler Rep. 2011 Jul 20. [Epub ahead of print].
24. Goodnight S, Harris W, Connor W, Illingworth D (1981) The effects of dietary omega 3 fatty acids on platelet composition and function in man: a prospective, controlled study blood Nov;58 (5):880-885.
25. Santos M, Fuset M, Ruano M, Moscardó A, Valles (2009) Effect of atorvastatin on platelet thromboxane A(2) synthesis in aspirintreated patients with acute myocardial infarction. JAm J Cardiol 15:104(12):1618-1623.
26. Morris MC, Sacks F, Rosner B (1993) Does fish oil lower blood pressure? A meta-analysis of controlled trials. Circulation 88:523- 533.
27. Geleijnse JM, Giltay EJ, Grobbee DE, Donders AR, Kok FJ (2002) Blood pressure response to fish oil supplementation: metaregression analysis of randomized trials. J Hypertens 20(8):1493-1499.
28. Sommerfield T, Price J, Hiatt WR. Omega-3 fatty acids for intermittent claudication. Cochrane database of systematic reviews.
29. Jones D, Hall J (2004) Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure and evidence from new hypertension trials. Hypertension 43(1):1-3.